Peptide Companion
Back to catalog
Peptide Companion
single
Growth Hormone
Vial: 1 mg

IGF-1 LR3 (1 mg Vial)

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects. This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity. This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications.

Detailed protocol below.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–220 mcg (0.02 mg)6 units (0.06 mL)
Weeks 3–440 mcg (0.04 mg)12 units (0.12 mL)
Weeks 5–850 mcg (0.05 mg)15 units (0.15 mL)
Supplies Needed
  • •Peptide Vials (IGF-1 LR3, 1 mg each):
  • •Insulin Syringes (U-100, 0.5 mL or 1 mL):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • •Sharps Container: For safe disposal of used needles and syringes.
  • •Fast-acting carbohydrate source: Glucose tablets or juice on hand during cycle to address potential hypoglycemia symptoms, especially during dose titration.
References

  • Biomolecules (MDPI)

    Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports

    View source

  • Dopinglinkki (FINCIS Anti-Doping Authority)

    Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information and safety overview

    View source

  • Mayo Clinic / IBM Micromedex

    Mecasermin (Subcutaneous route): Proper Use and Handling – guidance on IGF-1 administration timing with meals

    View source

  • Cell Sciences (Research Reagents)

    Recombinant Human LR3 IGF-1: Product technical datasheet including storage and stability specifications

    View source

  • Centers for Disease Control and Prevention (CDC)

    Preventing Unsafe Injection Practices: One Needle, One Syringe, Only One Time

    View source

  • Drugs.com

    Increlex (mecasermin) Dosage Guide: Clinical dosing and hypoglycemia management for IGF-1 therapy

    View source

  • AnabolicMinds Community Research Forum

    Storage and cycle considerations for IGF-1 LR3: Practical protocol discussions

    View source

  • Immunize.org (Immunization Action Coalition)

    How to Administer Subcutaneous Vaccine Injections: Site selection and rotation guidance

    View source

  • ReliaTech GmbH

    Human IGF-1 LR3 Protein Technical Specifications: Reconstitution and storage protocols

    View source

  • Mayo Clinic

    Mecasermin (subcutaneous route): Side effects and proper handling – solution inspection guidelines

    View source

  • Frontiers in Bioengineering & Biotechnology

    Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury

    View source

  • Drug Testing and Analysis (PubMed)

    Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes

    View source

  • NCBI Bookshelf

    5.6 Administering Subcutaneous Medications: Clinical best practices for subcutaneous injection technique

    View source

Educational content adapted from peptidedosages.com. Not medical advice.